The prognostic benefit from intermediate-dose cytarabine as consolidation therapy varies by cytogenetic subtype in t(8;21) acute myeloid leukemia: a retrospective cohort study
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.